Recombinant human interferon beta 1b produced in E. coli is a single non-glycosylated variant form of the human interferon beta-1b polypeptide chain. The interferon gene was cloned from human fibroblasts and altered to substitute Serine for the Cysteine at residue 17.
- Target Species
- Product Form
- Purified Recombinant protein - lyophilized
- Reconstitute with 0.1 ml distilled water. Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution.
- Purified recombinant interferon beta 1b expressed in E. coli
- Buffer Solution
- Lyophilized from a solution containing human albumin and dextrose
- Preservative Stabilisers
- None present
- The Specific activity determined using a viral resistance assay is of 32 x 106 IU/mg. The viral resistance assays used are the human WISH cell line and VSV, or the monkey VERO cell line and EMCV.
- >98% by SDS PAGE and HPLC analysis.
- Approx. Protein Concentrations
- 0.1 mg/ml after reconstitution
- Protein Molecular Weight
- 18.5 kDa (165 amino acid residues)
- Store at -20oC only.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.
- 3 months from date of reconstitution
- Entrez Gene
- GO Terms
transcription corepressor activity
interferon-alpha/beta receptor binding
induction of apoptosis
activation of caspase activity
negative regulation of cell proliferation
positive regulation of gene-specific transcription from RNA polymerase II promoter
natural killer cell activation
negative regulation of viral transcription
B cell proliferation
negative regulation of viral genome replication
positive regulation of innate immune response
regulation of MHC class I biosynthetic process
negative regulation of virion penetration into host cell
defense response to virus
type I interferon-mediated signaling pathway
regulation of type I interferon-mediated signaling pathway
cellular response to exogenous dsRNA
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of IFN Beta 1B
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Product Specific References
References for IFN Beta 1B
Happold, C. et al. (2014) Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells.
Mol Cancer Ther. 13: 948-61.
Wolpert, F. et al. (2015) Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells.
PLoS One. 10 (10): e0139603.
Eriksen, A.B. et al. (2015) Retinoic acid enhances the levels of IL-10 in TLR-stimulated B cells from patients with relapsing-remitting multiple sclerosis.
J Neuroimmunol. 278: 11-8.